See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Eid
World Cup
Artificial Intelligence
Donald Trump
Social Media
Elon Musk
Stock Markets
Education
Immigration
European Union
Soccer
Instagram
Published • loading... • Updated

Study of CAR T-cell therapy rese-cel in scleroderma enrolling in US

Summary by Scleroderma News
The open-label RESET-SSc trial is assessing the safety and efficacy of the CAR T-cell therapy rese-cel as a single intravenous infusion.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
Scleroderma NewsScleroderma News

Study of CAR T-cell therapy rese-cel in scleroderma enrolling in US

The open-label RESET-SSc trial is assessing the safety and efficacy of the CAR T-cell therapy rese-cel as a single intravenous infusion.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Scleroderma News broke the news in on Tuesday, April 1, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Maryland

Maryland

News
For You
SearchBlindspotLocal